Gonilert

Gonilert is a prescription intra‑articular injection that contains sodium hyaluronate as its active ingredient. Formulated for direct administration into the joint space, the product delivers a viscoelastic supplement to the synovial fluid. While the exact concentration is not disclosed, Gonilert is marketed in the European Union for use by healthcare professionals in the management of joint disorders. It belongs to the class of viscosupplements available.

Gonilert is indicated for the symptomatic treatment of osteoarthritis and other degenerative joint conditions where joint lubrication is compromised.

- Intra‑articular injection for knee osteoarthritis to improve joint function. - Management of hip or shoulder osteoarthritis when conventional therapy is insufficient. - Adjunct therapy for patients with limited response to oral analgesics or NSAIDs. - Use in patients awaiting joint replacement surgery to potentially delay the procedure. - Treatment of post‑traumatic joint stiffness to restore range of motion.

The safety profile of Gonilert reflects the typical reactions observed with intra‑articular hyaluronic acid preparations.

Common: - Transient joint pain or swelling at the injection site. - Mild warmth or flushing in the treated joint. - Temporary stiffness lasting a few days. - Minor bruising or bleeding at the puncture site.

Serious: - Acute joint infection (septic arthritis). - Allergic reaction such as rash, itching, or anaphylaxis.

Clinicians should evaluate patient history and joint condition before selecting Gonilert for intra‑articular therapy.

- Avoid use in patients with active joint infection or systemic infection. - Contraindicated in individuals with known hypersensitivity to hyaluronic acid or any formulation component. - Use caution in patients with bleeding disorders or those receiving anticoagulant therapy. - Assess renal function in patients with severe kidney disease, as clearance may be affected. - Do not inject into joints with severe cartilage loss where structural benefit is unlikely. - Monitor for signs of infection or inflammation after each injection. - Discuss potential risks with pregnant or breastfeeding women, although safety data are limited.

Gonilert may interact with other medications or substances that affect joint health or bleeding risk.

Avoid: - Concurrent intra‑articular corticosteroid injections within the same joint. - Simultaneous use of other viscosupplement products in the same joint.

Use with caution: - Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to bleeding risk at injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase local irritation. - Disease‑modifying antirheumatic drugs (DMARDs) in patients with inflammatory arthritis. - High‑dose vitamin C or supplements that affect collagen synthesis.